2024-10-13-PitchBook-PitchBook年二季度数字健康报告（英）_12页_5mb

EMERGING TECH RESEARCH: Q2 2024 Digital Health Report Summary

Market Trends

• VC Investment: Q2 2024 global VC funding for digital health was $1.5B, a slight quarterly decrease of 5.7% from Q1 2024, though the median deal size increased. Deal activity has bottomed out post-Q3 2023.
• Deal Volume: Q2 saw 119 deals, continuing a downward trend from prior quarters. Overall VC activity remains concentrated between $1.3B and $1.7B annually.
• Biggest Investments:
  • Sword Health raised $130M (Late stage) for a musculoskeletal platform, valuing ~$3B.
  • Talkiatry raised $130M (Series C) for a teletherapy platform.
  • FoodSmart secured $200M (Series D) for a telenutrition platform.
  • Large institutional players like Andreessen Horowitz and The Rise Fund were active.
• VC Exits: Few VC-backed exits ('goes public') in Q2. A notable acquisition was Altaris buying Sharecare for $540M ($50M premium to public price, reflecting value compression).
• Mergers & Acquisitions (M&A): Continued consolidation, particularly in Digital Therapeutics, Metabolic Health, and other health categories. Large players like Oura acquired Veri Health, leading (as of Q2 2024) in acquiring smaller, specialized firms, especially in metabolic health. Unprofitability remains an ongoing challenge for many startups, making them attractive acquisition targets.
• IPO Market: Public listings (Tempus, Waystar, Autonomix) occurred, but IPO sentiment in digital health remains cautious. While some later-stage companies aim for an end-2024 listing, an "IPO wave" is not expected, with any occurring viewed as exceptional.

Innovation Highlights

• Caregiver Support/Care Management: Growing VC interest in Tech-enabled care support, highlighting startups addressing caregiving needs.
• Personalized Supplements/Nutrition: Featured in innovation spotlights, with FoodSmart receiving significant funding. Platforms gaining traction in nutrition aimed at weight loss drugs are affecting the M&A landscape (e.g., Knownwell acquiring Alfie Health).
• Weight Loss/GLP-1 Drugs: Hims & Hers Health leveraging GLP-1 drug versions achieved strong sales growth (over 50% YoY), influencing M&A in related services.

Leading Companies & Areas

• Notable VC Backed Companies:

  • Papa, Electronic Caregiver, Vesta, Careforth, Cariloop, DUOS, Sage Health, ianacare.

• Star Company: Flo Health

  • Overview: Global consumer-facing women's health app leader with ~70M MAUs, user-centric platform for cycle tracking, insights, community.
  • Finances: Freemium model. Closed a $200M Series C in July 2024, pushing valuation over $1B (becoming the first purely digital consumer women's health app unicorn). Total raised now $299.5M.
  • Investor: General Atlantic led, alongside others.
  • Key Insight: The funding event stood out due to a challenging environment for consumer/DTC health platforms, signaling investor confidence in market leadership and revenue potential.
  • Recent Developments: CEO intended expansion into perimenopause/menopause, exploring M&A for new capabilities (personalized insights). Has strong revenue growth (50% expected top-line for 2024). Exit Predictor sees high M&A probability (62%).
  • Market Position: Minimal direct global-scale competition. Faces indirect competition from payer/employer platforms like Maven.

Key Observations

• Digital health VC activity has stabilized, with large, established players remaining key drivers.
• Expanding into adjacent health areas and leveraging existing user bases is a focus for top performers like Flo Health.
• M&A activity, particularly by consumer-facing health platforms or tech giants, is intensifying in relevant sectors (metabolic health, DTx).
• The outlook for the DTC consumer health segment, exemplified by Flo Health, is cautiously optimistic; exits require demonstrated profitability/growth and addressing market challenges, though they remain viable pathways.

Source: PitchBook